IP Library Granted Patent US 7,576,132
Granted Patent B2
US 7,576,132 · App. 11/146,620 · Granted Aug 18, 2009

Arginine silicate inositol complex and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,576,132
App. No.
11/146,620
Granted
Aug 18, 2009
Kind
B2
Abstract

A method for preventing and treating a variety of disease states and disorders is provided, comprising the administration of an arginine silicate inositol complex to an individual in the presence of medical therapy or absence of medical therapy. Examples of said disease states and disorders include bone and cartilage disorders and cardiovascular disease and its associated micro and macro vascular complications including infections and inflammation of all these diseases in combination or without. Advantageously, the amount of arginine silicate inositol complex administered per day is between about 2 mg/Kg body weight to 2,500 mg/Kg body weight or from a low dose to a higher dose to observe normal metabolic functions and healthy and the delivery is parenteral, oral or intravenous or topical by solid or liquid or both.

Claims (19)

1. A method of decreasing insulin resistance in an individual, comprising;

identifying an individual in need of decreased insulin resistance; and

administering to said individual an effective amount of an arginine silicate inositol complex.

2. The method of claim 1 , wherein said administering step is parenteral or oral.

3. The method of claim 1 , wherein said effective amount of said arginine silicate inositol complex is between about 2 mg/kg body weight and about 2,500 mg/kg body weight.

4. The method of claim 3 , wherein said effective amount of said arginine silicate complex is between about 5 mg/kg body weight and about 1,000 mg/kg body weight.

5. The method of claim 1 , wherein said individual is a mammal.

6. A method for increasing nitric oxide production in an individual, comprising the step of administering to said individual an effective amount of an arginine silicate inositol complex.

7. The method of claim 6 , wherein said administering step is parenteral or oral.

8. The method of claim 6 , wherein said effective amount of said arginine silicate complex is between about 2 mg/kg body weight and about 2,500 mg/kg body weight.

9. The method of claim 7 , wherein said individual is a mammal.

10. A method for treating a disorder caused by or exacerbated by reduced levels of nitric oxide by increasing concentrations of nitric oxide in an individual, comprising;

identifying an individual in need of an increased concentration of nitric oxide; and

administering to said individual an effective amount of an arginine silicate inositol complex.

11. The method of claim 10 , wherein said disorder is selected from the group consisting of pulmonary hypertension, renal disease, hypertension, diabetes, hypercholesterolemia, hyperglycemia, heart failure, Fabry's disease, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, Crohn's disease, ulcerative colitis, perinatal asphyxia, meconium aspiration syndrome, Group B strep sepsis, congenital diaphragmatic hernia, isehemic heart disease, hyperhomocysteinemia, multiple sclerosis, Takayasu's arteritis, autosomal dominant polycystie kidney disease, end-stage renal failure, and liver disease.

12. The method of claim 10 , wherein said arginine silicate inositol complex is administered parenterally or orally.

13. The method of claim 10 , further comprising administering a second beneficial agent effective in treating a disorder caused by or exacerbated by reduced levels of NO, wherein said second beneficial agent is a conventional therapy for NO deficiencies.

14. The method of claim 10 , wherein said effective amount of arginine silicate complex is between about 2 mg/kg body weight and about 2,500 mg/kg body weight.

15. The method of claim 10 , wherein said individual is a mammal.

Assignments (4)
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2018
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 047666/0467 →
CHANGE OF NAME Recorded Jun 14, 2012
From: N21 ACQUISITION HOLDING, LLC
To: JDS THERAPEUTICS, LLC
Reel/Frame 028603/0993 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2012
From: NUTRITION 21, INC.
To: N21 ACQUISITION HOLDING, LLC
Reel/Frame 027545/0079 →